

## CLAIMS

5    1. Use of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, an optically active enantiomer or mixture of enantiomers thereof and a pharmaceutically acceptable salt of the racemic or optically active compound in the preparation of a pharmaceutical composition for the treatment or

10   prevention of neurodegenerative diseases.

2. An use as claimed in claim 1 wherein the chemical substance is (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride.

15   3. An use as claimed in claim 2 wherein the chemical substance is a salt of (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride.

20   4. An use as claimed in claim 3 wherein the chemical substance is (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate.

25   5. An use as claimed in any of claims 1 to 4 wherein the neurodegenerative disease is amyotrophic lateral sclerosis.

30   6. Method of treatment or prevention of a neurodegenerative disease wherein a therapeutically effective amount of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, an optically active enantiomer or mixture of

enantiomers thereof and a pharmaceutically acceptable salt of the racemic or optically active compound is administered to a patient.

7. A method as claimed in claim 6 wherein the chemical substance is (+)-R-  
5 N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride.
8. A method as claimed in claim 7 wherein the chemical substance is a salt  
of (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carbox-  
10 imidoyl chloride.
9. A method as claimed in claim 8 wherein the chemical substance is (+)-R-  
N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate.
- 15 10. A method as claimed in any of claims 6 to 9 wherein the neurodegenerative disease is amyotrophic lateral sclerosis.